REGN

Regeneron Pharmaceuticals
D

REGN

750.53
USD
-1.70
(-0.23%)
قبل الجلسة·752.00USD+1.47(+0.20%)
حجم التداول
42,663
الربح لكل سهم
50
العائد الربحي
0.49
P/E
19
حجم السوق
77,270,807,144
أصول ذات صلة الأخبار المقالات
المزيد

العنوان: Regeneron Pharmaceuticals

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.